Human Fas associated factor 1 (hFAF1) is a pro-apoptotic scaffolding protein containing ubiquitin-associating (UBA), ubiquitin like 1 and 2 (UBL1, UBL2), and ubiquitin regulatory X (UBX) domains. hFAF1 interacts with polyubiquitinated proteins via its N-terminal UBA domain and with valosin containing protein (VCP) via its C-terminal UBX domain. Overexpression of hFAF1 or its N-terminal UBA domain significantly increases cell death by increasing the degradation of polyubiquitinated proteins. In this study, we investigated whether hFAF1, whose expression level is reduced in cervical cancer, plays a role in tumor formation. We found that HeLa cells overexpressing full-length hFAF1 or the hFAF1 UBA domain alone, significantly suppressed the anchorage independent tumor growth in soft agar colony formation, increased cell death, and activated JNK and caspase 3. Employing UBA-specific tandem immunoprecipitation, we identified moieties specifically interacting with UBA domain of hFAF1, and found that polyubiquitinated Hsp70s are recruited to UBA domain. We also demonstrated that hFAF1 overexpression promotes Hsp70 degradation via the proteasome. We further found that mutating the UBA domain (I41N), as well as knocking down hFAF1 with specific RNAi, abolishs its ability to increase the proteasomal degradation of Hsp70. These findings suggest that hFAF1 inhibits tumor formation by increasing the degradation of Hsp70 mediated via its UBA domain.
References
[1]
Chu K, Niu X, Williams LT (1995) A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc Natl Acad Sci U S A 92: 11894–11898.
[2]
Ryu SW, Lee SJ, Park MY, Jun JI, Jung YK, et al. (2003) Fas-associated factor 1, FAF1, is a member of Fas death-inducing signaling complex. J Biol Chem 278: 24003–24010.
[3]
Ryu SW, Kim E (2001) Apoptosis induced by human Fas-associated factor 1, hFAF1, requires its ubiquitin homologous domain, but not the Fas-binding domain. Biochem Biophys Res Commun 286: 1027–1032.
[4]
Park MY, Jang HD, Lee SY, Lee KJ, Kim E (2004) Fas-associated factor-1 inhibits nuclear factor-kappaB (NF-kappaB) activity by interfering with nuclear translocation of the RelA (p65) subunit of NF-kappaB. J Biol Chem 279: 2544–2549.
[5]
Park MY, Moon JH, Lee KS, Choi HI, Chung J, et al. (2007) FAF1 suppresses IkappaB kinase (IKK) activation by disrupting the IKK complex assembly. J Biol Chem 282: 27572–27577.
[6]
Hidalgo A, Baudis M, Petersen I, Arreola H, Pina P, et al. (2005) Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer 5: 77.
[7]
Bjorling-Poulsen M, Seitz G, Guerra B, Issinger OG (2003) The pro-apoptotic FAS-associated factor 1 is specifically reduced in human gastric carcinomas. Int J Oncol 23: 1015–1023.
[8]
Kim HJ, Song EJ, Lee YS, Kim E, Lee KJ (2005) Human Fas-associated factor 1 interacts with heat shock protein 70 and negatively regulates chaperone activity. J Biol Chem 280: 8125–8133.
[9]
Song EJ, Yim SH, Kim E, Kim NS, Lee KJ (2005) Human Fas-associated factor 1, interacting with ubiquitinated proteins and valosin-containing protein, is involved in the ubiquitin-proteasome pathway. Mol Cell Biol 25: 2511–2524.
[10]
Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67: 425–479.
[11]
Hershko A (2005) The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ 12: 1191–1197.
[12]
Hurley JH, Lee S, Prag G (2006) Ubiquitin-binding domains. Biochem J 399: 361–372.
[13]
Kirkin V, Dikic I (2007) Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr Opin Cell Biol 19: 199–205.
[14]
Buchberger A (2002) From UBA to UBX: new words in the ubiquitin vocabulary. Trends Cell Biol 12: 216–221.
[15]
Chen L, Madura K (2002) Rad23 promotes the targeting of proteolytic substrates to the proteasome. Mol Cell Biol 22: 4902–4913.
[16]
Verma R, Oania R, Graumann J, Deshaies RJ (2004) Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 118: 99–110.
[17]
Song JS, Park JK, Lee JJ, Choi YS, Ryu KS, et al. (2009) Structure and Interaction of Ubiquitin-Associated Domain of Human Fas Associated Factor 1. Protein Sci 18: 2265–2276.
[18]
Aghdassi A, Phillips P, Dudeja V, Dhaulakhandi D, Sharif R, et al. (2007) Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 67: 616–625.
[19]
Qian SB, McDonough H, Boellmann F, Cyr DM, Patterson C (2006) CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature 440: 551–555.
[20]
Liu M, Aneja R, Sun X, Xie S, Wang H, et al. (2008) Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase. J Biol Chem 283: 35783–35788.
[21]
Moore DJ, West AB, Dikeman DA, Dawson VL, Dawson TM (2008) Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem 105: 1806–1819.
Mueller TD, Feigon J (2002) Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. J Mol Biol 319: 1243–1255.
[24]
Varadan R, Assfalg M, Raasi S, Pickart C, Fushman D (2005) Structural determinants for selective recognition of a Lys48-linked polyubiquitin chain by a UBA domain. Mol Cell 18: 687–698.
[25]
Raasi S, Varadan R, Fushman D, Pickart CM (2005) Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nat Struct Mol Biol 12: 708–714.
[26]
Saracco SA, Hansson M, Scalf M, Walker JM, Smith LM, et al. (2009) Tandem affinity purification and mass spectrometric analysis of ubiquitylated proteins in Arabidopsis. Plant J 59: 344–358.
[27]
Kundrat L, Regan L (2010) Identification of Residues on Hsp70 and Hsp90 ubiquitinated by the cochaperone CHIP. J Mol Biol 395: 587–594.
[28]
Ciani B, Layfield R, Cavey JR, Sheppard PW, Searle MS (2003) Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone. J Biol Chem 278: 37409–37412.
[29]
Yip KH, Feng H, Pavlos NJ, Zheng MH, Xu J (2006) p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone. Am J Pathol 169: 503–514.
[30]
Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, et al. (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801–805.
[31]
Daniel DC (2002) Highlight: BRCA1 and BRCA2 proteins in breast cancer. Microsc Res Tech 59: 68–83.
[32]
Baer R, Ludwig T (2002) The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 12: 86–91.
[33]
Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM (2001) Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A 98: 5134–5139.
[34]
Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360.
[35]
Kim M, Lee JH, Lee SY, Kim E, Chung J (2006) Caspar, a suppressor of antibacterial immunity in Drosophila. Proc Natl Acad Sci U S A 103: 16358–16363.
[36]
Alexandru G, Graumann J, Smith GT, Kolawa NJ, Fang R, et al. (2008) UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1alpha turnover. Cell 134: 804–816.
[37]
Seo J, Jeong J, Kim YM, Hwang N, Paek E, et al. (2008) Strategy for comprehensive identification of post-translational modifications in cellular proteins, including low abundant modifications: application to glyceraldehyde-3-phosphate dehydrogenase. J Proteome Res 7: 587–602.
[38]
Na S, Jeong J, Park H, Lee KJ, Paek E (2008) Unrestrictive identification of multiple post-translational modifications from tandem mass spectrometry using an error-tolerant algorithm based on an extended sequence tag approach. Mol Cell Proteomics 12: 2452–2456.
